News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
764,476 Results
Type
Article (54406)
Company Profile (475)
Press Release (709594)
Multimedia
Podcasts (110)
Webinars (14)
Section
Business (218223)
Career Advice (2874)
Deals (37438)
Drug Delivery (121)
Drug Development (87282)
Employer Resources (186)
FDA (17206)
Job Trends (16120)
News (370502)
Policy (35723)
Tag
Academia (2922)
Academic (1)
Accelerated approval (7)
Adcomms (30)
Allergies (100)
Alliances (53535)
ALS (112)
Alzheimer's disease (1523)
Antibody-drug conjugate (ADC) (178)
Approvals (17157)
Artificial intelligence (322)
Autoimmune disease (31)
Automation (18)
Bankruptcy (390)
Best Places to Work (12332)
BIOSECURE Act (21)
Biosimilars (121)
Biotechnology (356)
Bladder cancer (95)
Brain cancer (36)
Breast cancer (370)
Cancer (2839)
Cardiovascular disease (229)
Career advice (2413)
Career pathing (34)
CAR-T (191)
CDC (32)
Cell therapy (516)
Cervical cancer (22)
Clinical research (71192)
Collaboration (1019)
Company closure (3)
Compensation (641)
Complete response letters (28)
COVID-19 (2841)
CRISPR (64)
C-suite (313)
Cystic fibrosis (114)
Data (2838)
Decentralized trials (2)
Denatured (36)
Depression (64)
Diabetes (316)
Diagnostics (6770)
Digital health (22)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (140)
Drug pricing (141)
Drug shortages (30)
Duchenne muscular dystrophy (121)
Earnings (90625)
Editorial (47)
Employer branding (24)
Employer resources (160)
Events (122820)
Executive appointments (871)
FDA (18761)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (907)
Gene editing (139)
Generative AI (25)
Gene therapy (399)
GLP-1 (859)
Government (4959)
Grass and pollen (6)
Guidances (179)
Healthcare (20229)
Huntington's disease (29)
IgA nephropathy (39)
Immunology and inflammation (165)
Immuno-oncology (7)
Indications (36)
Infectious disease (3010)
Inflammatory bowel disease (160)
Inflation Reduction Act (12)
Influenza (63)
Intellectual property (113)
Interviews (557)
IPO (17264)
IRA (51)
Job creations (4225)
Job search strategy (1986)
Kidney cancer (15)
Labor market (49)
Layoffs (557)
Leadership (25)
Legal (8758)
Liver cancer (83)
Lung cancer (404)
Lymphoma (195)
Machine learning (9)
Management (62)
Manufacturing (380)
MASH (91)
Medical device (14121)
Medtech (14126)
Mergers & acquisitions (20832)
Metabolic disorders (844)
Multiple sclerosis (99)
NASH (23)
Neurodegenerative disease (130)
Neuropsychiatric disorders (36)
Neuroscience (2211)
NextGen: Class of 2025 (7254)
Non-profit (4906)
Now hiring (46)
Obesity (445)
Opinion (272)
Ovarian cancer (96)
Pain (112)
Pancreatic cancer (107)
Parkinson's disease (183)
Partnered (22)
Patents (290)
Patient recruitment (140)
Peanut (53)
People (62787)
Pharmaceutical (94)
Pharmacy benefit managers (23)
Phase I (22204)
Phase II (31269)
Phase III (23252)
Pipeline (1586)
Policy (209)
Postmarket research (2939)
Preclinical (9576)
Press Release (70)
Prostate cancer (137)
Psychedelics (39)
Radiopharmaceuticals (275)
Rare diseases (478)
Real estate (6494)
Recruiting (72)
Regulatory (24510)
Reports (51)
Research institute (2589)
Resumes & cover letters (455)
Rett syndrome (9)
RNA editing (9)
RSV (50)
Schizophrenia (90)
Series A (157)
Series B (104)
Service/supplier (13)
Sickle cell disease (64)
Special edition (21)
Spinal muscular atrophy (159)
Sponsored (34)
Startups (3945)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (62)
The Weekly (72)
Vaccines (839)
Venture capitalists (51)
Weight loss (296)
Women's health (46)
Worklife (20)
Date
Today (27)
Last 7 days (492)
Last 30 days (2430)
Last 365 days (33471)
2025 (15711)
2024 (37241)
2023 (42046)
2022 (53337)
2021 (58018)
2020 (56723)
2019 (49934)
2018 (37763)
2017 (34839)
2016 (34730)
2015 (40810)
2014 (34949)
2013 (30241)
2012 (32224)
2011 (32693)
2010 (30934)
Location
Africa (927)
Alabama (65)
Alaska (7)
Arizona (257)
Arkansas (14)
Asia (43893)
Australia (7802)
California (7318)
Canada (2287)
China (664)
Colorado (311)
Connecticut (322)
Delaware (185)
Europe (97342)
Florida (1090)
Georgia (241)
Idaho (62)
Illinois (655)
India (28)
Indiana (355)
Iowa (16)
Japan (216)
Kansas (112)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1038)
Massachusetts (5531)
Michigan (247)
Minnesota (451)
Mississippi (3)
Missouri (93)
Montana (31)
Nebraska (25)
Nevada (77)
New Hampshire (71)
New Jersey (2033)
New Mexico (31)
New York (2053)
North Carolina (1171)
North Dakota (9)
Northern California (3189)
Ohio (232)
Oklahoma (15)
Oregon (40)
Pennsylvania (1573)
Puerto Rico (17)
Rhode Island (39)
South America (1306)
South Carolina (33)
South Dakota (1)
Southern California (2717)
Tennessee (121)
Texas (1086)
United States (27410)
Utah (216)
Virginia (181)
Washington D.C. (77)
Washington State (635)
West Virginia (4)
Wisconsin (67)
764,476 Results for "sarepta therapeutics formerly known as avi biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.
December 4, 2024
·
3 min read
·
Annalee Armstrong
Podcasts
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations without advisor input; Trump CDC nominee Dave Weldon pulled at last minute; and FDA decisions expected for Alnylam’s Amvuttra in ATTR-CM and Milestone’s etripamil in tachycardia.
March 19, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Sarepta Therapeutics Provides Update on ELEVIDYS
April 7, 2025
·
8 min read
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
After a patient taking the Duchenne muscular dystrophy gene therapy Elevydis died of liver injury, Sarepta will update the label to reflect the safety signal.
March 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
May 8, 2025
·
1 min read
Press Releases
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
May 13, 2025
·
10 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
April 22, 2025
·
1 min read
Press Releases
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
April 15, 2025
·
8 min read
Press Releases
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
May 16, 2025
·
10 min read
1 of 76,448
Next
